ClinicalTrials.gg
CompletedNCT03301181Updated Nov 1, 2019

Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects

A Phase 1 interventional study of BGB-3111 (Arm A) and Rifampin in Healthy Volunteers: Asian, Non-Asian, sponsored by BeiGene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-01.

Sponsored by BeiGene · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Phase 1 study in healthy subjects to determine the effect of rifampin (Part A) or itraconazole (Part B) on the pharmacokinetics of BGB-3111

Read the detailed description

This is a Phase 1 open-label, parallel-group study in healthy subjects. Subjects in Part A will receive a single dose of BGB-3111 before and during consecutive daily doses of strong cytochrome P450 CYP3A inducer, rifampin, to investigate its effect on the pharmacokinetics of BGB-3111. Following an interim data analysis, subjects in Part B will receive a single dose of BGB-3111 before and during consecutive daily doses of strong CYP3A inhibitor, itraconazole, to investigate its effect on the pharmacokinetics of BGB-3111.

02

Conditions studied

  • Healthy Volunteers: Asian, Non-Asian
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI)18 - 32 kg/m2, inclusive.
  2. Subjects of Asian (first- or second-generation) and non-Asian descent.
  3. In good general health as assessed by the Investigator.
  4. Females must be nonpregnant and nonlactating, and females of will agree to use required .
  5. Males without a vasectomy will agree to use required barrier contraception, and will agree to not donate sperm from the time of the first dose of BGB-3111 until ≥90 days after the last dose of BGB-3111.Able to comprehend and willing to sign consent.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history or presence of any clinically significant disease.
  2. Evidence of bacterial, viral, fungal, parasitic infections within 4 weeks prior to the first dose of study drug.
  3. History of significant , intolerance, or allergy to any drug compound, food, or other substance.
  4. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
  5. History of alcoholism or drug/chemical abuse within prior year.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Arm A

    Approximately 20 subjects to receive BGB-3111 and rifampin

    Drug: BGB-3111 (Arm A) · Drug: Rifampin

  • Experimental
    Arm B

    Approximately 20 subjects to receive BGB-3111 and itraconazole

    Drug: BGB-3111 (Arm B) · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma concentration of BGB-3111 and rifampin to evaluate protocol specified PK parameters

    Time frame: Part A: Days 1 and 10

  2. Plasma concentration of BGB-3111 and itraconazole to evaluate protocol specified PK parameters

    Time frame: Part B: Days 1 and 6

Secondary outcomes

  1. Safety as assessed by adverse events

    Time frame: Part A: up to 19 days: Part B: up to 14 days

  2. Safety as assessed by electrocardiogram (ECG) measurements

    Time frame: Part A: Days 1 and 10, from screening to end of study visit; up to Day 19; Part B: Days 1 and 6, from screening to end of study visit; up to Day 14

07

Study locations

1 site
  • West Coast Clinical Trials (WCCT)
    Cypress, California 90630, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Nov 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 4, 2017
StartActual
Sep 18, 2017
Primary completionActual
Nov 7, 2017
CompletionActual
Nov 13, 2017
Last update
Nov 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03301181
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Sep 18, 2017
Primary completion
Nov 7, 2017
Completion
Nov 13, 2017
Last update
Nov 1, 2019

Study contacts

William Novotny, MD
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion